<p>隨着亞洲市場在全球經濟變動中經歷波動，投資者越來越關注在該地區多樣化的市場中識別機會。在這種環境下，似乎被低估的股票為那些希望利用潛在市場低效的人提供了引人注目的可能性。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>SRE Holdings (TSE:2980)</td>
<td>¥3180.00</td>
<td>¥6197.35</td>
<td>48.7%</td>
</tr>
<tr>
<td>SILICON2 (KOSDAQ:A257720)</td>
<td>₩53700.00</td>
<td>₩105825.30</td>
<td>49.3%</td>
</tr>
<tr>
<td>Nanya Technology (TWSE:2408)</td>
<td>NT$43.95</td>
<td>NT$87.09</td>
<td>49.5%</td>
</tr>
<tr>
<td>江蘇雲億電氣有限公司 (SZSE:300304)</td>
<td>CN¥11.08</td>
<td>CN¥22.02</td>
<td>49.7%</td>
</tr>
<tr>
<td>Heartland Group Holdings (NZSE:HGH)</td>
<td>NZ$0.80</td>
<td>NZ$1.58</td>
<td>49.5%</td>
</tr>
<tr>
<td>廣東丸美生物科技 (SHSE:603983)</td>
<td>CN¥40.73</td>
<td>CN¥79.37</td>
<td>48.7%</td>
</tr>
<tr>
<td>GEM (SZSE:002340)</td>
<td>CN¥6.54</td>
<td>CN¥13.00</td>
<td>49.7%</td>
</tr>
<tr>
<td>Finger (KOSDAQ:A163730)</td>
<td>₩13480.00</td>
<td>₩26287.84</td>
<td>48.7%</td>
</tr>
<tr>
<td>cottaLTD (TSE:3359)</td>
<td>¥442.00</td>
<td>¥868.15</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology (TWSE:6533)</td>
<td>NT$276.50</td>
<td>NT$541.44</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 282 只被低估的亞洲股票的完整列表。</p>
<p>我們將從我們的篩選結果中審查一些選項。</p>
<h2>中糧糖業控股有限公司 (SHSE:600737)</h2>
<p><strong>概述：</strong> 中糧糖業控股有限公司在中國及國際上從事糖和番茄加工，市值為 CN¥218.4 億。</p>
<p><strong>運營：</strong> 中糧糖業控股有限公司主要通過其在國內和國際市場的糖和番茄加工活動產生收入。</p>
<p><strong>公允價值折扣估計：</strong> 40.3%</p>
<p>中糧糖業控股有限公司的交易價格為 CN¥10.21，顯著低於其估計的公允價值 CN¥17.11，表明基於折現現金流分析的潛在低估。預計該公司的收益將以每年 36.89% 的速度顯著增長，超過中國市場平均增長率 23.6%。儘管預計收入將以每年 18% 的速度強勁增長，但投資者在考慮長期現金流可持續性時應注意不穩定的股息記錄。</p>
<ul>
<li>我們編制的增長報告表明，中糧糖業控股有限公司的未來前景可能向好。</li>
<li>在這裏深入瞭解中糧糖業控股有限公司的詳細財務健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93c71ee-149b-4a67-bc29-bddbe7101502/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93c71ee-149b-4a67-bc29-bddbe7101502/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:600737 截至 2025 年 8 月的折現現金流</p>
<h2>廣東丸美生物科技 (SHSE:603983)</h2>
<p><strong>概述：</strong> 廣東丸美生物科技有限公司專注於中國的化妝品研究、設計、生產、銷售和服務，市值為 CN¥163.3 億。</p>
<p><strong>運營：</strong> 公司的收入主要來自其個人產品部門，該部門產生了 CN¥31.6 億的收入。</p>
<p><strong>公允價值折扣估計：</strong> 48.7%</p>
<p>廣東丸美生物科技的交易價格為 CN¥40.73，顯著低於其估計的公允價值 CN¥79.37，突顯出基於折現現金流分析的潛在低估。預計該公司的收益將以每年 23.7% 的速度增長，略微超過中國市場的平均增長率。預計收入將以每年 21.5% 的速度增長，超出市場預期；然而，1.84% 的股息收益率缺乏自由現金流的覆蓋，股本回報率保持在 15.2% 的適度水平。</p>
<ul>
<li>我們的廣東丸美生物科技增長報告中的分析暗示未來財務表現強勁。</li>
<li>在這裏深入瞭解廣東丸美生物科技的完整分析健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fdc12f-9db8-445d-80e6-9b615dd8952d/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fdc12f-9db8-445d-80e6-9b615dd8952d/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:603983 截至 2025 年 8 月的折現現金流</p>
<h2>MeHow Innovative (SZSE:301363)</h2>
<p><strong>概述：</strong> MeHow Innovative Ltd. 是一家在中國及國際上設計、開發、製造和銷售精密醫療設備組件和產品的公司，市值為 CN¥113.3 億。</p>
<p><strong>運營：</strong> 收入部門（以百萬 CN¥計）：</p>
<p><strong>公允價值折扣估計：</strong> 32.6%</p>
<p>MeHow Innovative 的交易價格為 CN¥20.03，低於其估計的公允價值 CN¥29.72，表明基於折現現金流分析的低估。預計未來三年收益將以每年 22.87% 的速度增長，儘管略微落後於更廣泛的中國市場增長率 23.6%。預計收入將以每年 21.4% 的速度強勁增長，超過市場平均水平 12.6%，儘管預計股本回報率僅為 13.1%。</p>
<ul>
<li>在審查我們最新的增長報告後，MeHow Innovative 的預期財務表現似乎相當樂觀。</li>
<li>點擊探索我們在 MeHow Innovative 的資產負債表健康報告中的詳細發現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/52088d4a-b234-4222-b5fb-5f505cb6f054/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/52088d4a-b234-4222-b5fb-5f505cb6f054/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:301363 截至 2025 年 8 月的折現現金流</p>
<h2>利用機會</h2>
<ul>
<li>點擊此鏈接訪問基於現金流的 282 只被低估的亞洲股票的完整範圍。</li>
<li>已經擁有這些公司？將您的投資組合鏈接到 Simply Wall St，並獲取有關您股票的新警告信號的提醒。</li>
<li>利用 Simply Wall St 最大化您的投資潛力，這是一款提供全球市場洞察的綜合應用，免費提供。</li>
</ul>
<h2>尋找新視角？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健股息支付者來多樣化您的投資組合，以應對潛在的市場動盪。</li>
<li>通過分析師和管理層的樂觀前景，推動您的投資組合中顯示強勁增長潛力的公司。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

中糧糖業

丸美生物

<p>隨着亞洲市場波動，投資者正在尋找被低估的股票。值得注意的包括 SRE Holdings、SILICON2 和南亞科技，預計折扣在 48.7% 到 49.5% 之間。中糧糖業和廣東丸美生物也顯示出顯著的低估，折扣分別為 40.3% 和 48.7%。這兩家公司預計將經歷強勁的盈利增長，儘管對股息可持續性存在擔憂。分析表明，基於現金流評估，這些被低估的股票可能存在投資機會</p>

<p>As Asian markets experience fluctuations amid global economic shifts, investors are increasingly focused on identifying opportunities within the region's diverse landscape. In this environment, stocks that appear undervalued present intriguing possibilities for those looking to capitalize on potential market inefficiencies.</p>
<div class="lb-trans"><p>隨着亞洲市場在全球經濟變動中經歷波動，投資者越來越關注在該地區多樣化的市場中識別機會。在這種環境下，似乎被低估的股票為那些希望利用潛在市場低效的人提供了引人注目的可能性。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>SRE Holdings (TSE:2980)</td>
<td>¥3180.00</td>
<td>¥6197.35</td>
<td>48.7%</td>
</tr>
<tr>
<td>SILICON2 (KOSDAQ:A257720)</td>
<td>₩53700.00</td>
<td>₩105825.30</td>
<td>49.3%</td>
</tr>
<tr>
<td>Nanya Technology (TWSE:2408)</td>
<td>NT$43.95</td>
<td>NT$87.09</td>
<td>49.5%</td>
</tr>
<tr>
<td>Jiangsu Yunyi ElectricLtd (SZSE:300304)</td>
<td>CN¥11.08</td>
<td>CN¥22.02</td>
<td>49.7%</td>
</tr>
<tr>
<td>Heartland Group Holdings (NZSE:HGH)</td>
<td>NZ$0.80</td>
<td>NZ$1.58</td>
<td>49.5%</td>
</tr>
<tr>
<td>Guangdong Marubi Biotechnology (SHSE:603983)</td>
<td>CN¥40.73</td>
<td>CN¥79.37</td>
<td>48.7%</td>
</tr>
<tr>
<td>GEM (SZSE:002340)</td>
<td>CN¥6.54</td>
<td>CN¥13.00</td>
<td>49.7%</td>
</tr>
<tr>
<td>Finger (KOSDAQ:A163730)</td>
<td>₩13480.00</td>
<td>₩26287.84</td>
<td>48.7%</td>
</tr>
<tr>
<td>cottaLTD (TSE:3359)</td>
<td>¥442.00</td>
<td>¥868.15</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology (TWSE:6533)</td>
<td>NT$276.50</td>
<td>NT$541.44</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>SRE Holdings (TSE:2980)</td>
<td>¥3180.00</td>
<td>¥6197.35</td>
<td>48.7%</td>
</tr>
<tr>
<td>SILICON2 (KOSDAQ:A257720)</td>
<td>₩53700.00</td>
<td>₩105825.30</td>
<td>49.3%</td>
</tr>
<tr>
<td>Nanya Technology (TWSE:2408)</td>
<td>NT$43.95</td>
<td>NT$87.09</td>
<td>49.5%</td>
</tr>
<tr>
<td>江蘇雲億電氣有限公司 (SZSE:300304)</td>
<td>CN¥11.08</td>
<td>CN¥22.02</td>
<td>49.7%</td>
</tr>
<tr>
<td>Heartland Group Holdings (NZSE:HGH)</td>
<td>NZ$0.80</td>
<td>NZ$1.58</td>
<td>49.5%</td>
</tr>
<tr>
<td>廣東丸美生物科技 (SHSE:603983)</td>
<td>CN¥40.73</td>
<td>CN¥79.37</td>
<td>48.7%</td>
</tr>
<tr>
<td>GEM (SZSE:002340)</td>
<td>CN¥6.54</td>
<td>CN¥13.00</td>
<td>49.7%</td>
</tr>
<tr>
<td>Finger (KOSDAQ:A163730)</td>
<td>₩13480.00</td>
<td>₩26287.84</td>
<td>48.7%</td>
</tr>
<tr>
<td>cottaLTD (TSE:3359)</td>
<td>¥442.00</td>
<td>¥868.15</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology (TWSE:6533)</td>
<td>NT$276.50</td>
<td>NT$541.44</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 282 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 282 只被低估的亞洲股票的完整列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我們將從我們的篩選結果中審查一些選項。</p>
</div><h2>Cofco Sugar HoldingLTD (SHSE:600737)</h2>
<div class="lb-trans"><h2>中糧糖業控股有限公司 (SHSE:600737)</h2>
</div><p><strong>Overview:</strong> Cofco Sugar Holding Co., Ltd. operates in sugar and tomato processing both in China and internationally, with a market cap of CN¥21.84 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中糧糖業控股有限公司在中國及國際上從事糖和番茄加工，市值為 CN¥218.4 億。</p>
</div><p><strong>Operations:</strong> Cofco Sugar Holding CO., LTD. generates revenue primarily through its activities in sugar and tomato processing across domestic and international markets.</p>
<div class="lb-trans"><p><strong>運營：</strong> 中糧糖業控股有限公司主要通過其在國內和國際市場的糖和番茄加工活動產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 40.3%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 40.3%</p>
</div><p>Cofco Sugar Holding LTD is trading at CN¥10.21, significantly below its estimated fair value of CN¥17.11, indicating potential undervaluation based on discounted cash flow analysis. The company's earnings are forecast to grow significantly at 36.89% annually, outpacing the Chinese market's average growth rate of 23.6%. While revenue growth is expected to be robust at 18% per year, investors should note the unstable dividend track record when considering long-term cash flow sustainability.</p>
<div class="lb-trans"><p>中糧糖業控股有限公司的交易價格為 CN¥10.21，顯著低於其估計的公允價值 CN¥17.11，表明基於折現現金流分析的潛在低估。預計該公司的收益將以每年 36.89% 的速度顯著增長，超過中國市場平均增長率 23.6%。儘管預計收入將以每年 18% 的速度強勁增長，但投資者在考慮長期現金流可持續性時應注意不穩定的股息記錄。</p>
</div><ul>
<li>The growth report we've compiled suggests that Cofco Sugar HoldingLTD's future prospects could be on the up.</li>
<li>Dive into the specifics of Cofco Sugar HoldingLTD here with our thorough financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們編制的增長報告表明，中糧糖業控股有限公司的未來前景可能向好。</li>
<li>在這裏深入瞭解中糧糖業控股有限公司的詳細財務健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93c71ee-149b-4a67-bc29-bddbe7101502/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/d93c71ee-149b-4a67-bc29-bddbe7101502/chart/dcf?theme=light"/></p>
<p>SHSE:600737 Discounted Cash Flow as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:600737 截至 2025 年 8 月的折現現金流</p>
</div><h2>Guangdong Marubi Biotechnology (SHSE:603983)</h2>
<div class="lb-trans"><h2>廣東丸美生物科技 (SHSE:603983)</h2>
</div><p><strong>Overview:</strong> Guangdong Marubi Biotechnology Co., Ltd. focuses on the research, design, production, sale, and service of cosmetics in China with a market cap of CN¥16.33 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 廣東丸美生物科技有限公司專注於中國的化妝品研究、設計、生產、銷售和服務，市值為 CN¥163.3 億。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its Personal Products segment, which generated CN¥3.16 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其個人產品部門，該部門產生了 CN¥31.6 億的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 48.7%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 48.7%</p>
</div><p>Guangdong Marubi Biotechnology is trading at CN¥40.73, significantly below its estimated fair value of CN¥79.37, highlighting potential undervaluation based on discounted cash flow analysis. The company's earnings are forecast to grow at 23.7% annually, slightly outpacing the Chinese market's average growth rate. Revenue is expected to increase by 21.5% per year, surpassing market expectations; however, the dividend yield of 1.84% lacks coverage from free cash flows and return on equity remains modest at 15.2%.</p>
<div class="lb-trans"><p>廣東丸美生物科技的交易價格為 CN¥40.73，顯著低於其估計的公允價值 CN¥79.37，突顯出基於折現現金流分析的潛在低估。預計該公司的收益將以每年 23.7% 的速度增長，略微超過中國市場的平均增長率。預計收入將以每年 21.5% 的速度增長，超出市場預期；然而，1.84% 的股息收益率缺乏自由現金流的覆蓋，股本回報率保持在 15.2% 的適度水平。</p>
</div><ul>
<li>The analysis detailed in our Guangdong Marubi Biotechnology growth report hints at robust future financial performance.</li>
<li>Delve into the full analysis health report here for a deeper understanding of Guangdong Marubi Biotechnology.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的廣東丸美生物科技增長報告中的分析暗示未來財務表現強勁。</li>
<li>在這裏深入瞭解廣東丸美生物科技的完整分析健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fdc12f-9db8-445d-80e6-9b615dd8952d/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/a3fdc12f-9db8-445d-80e6-9b615dd8952d/chart/dcf?theme=light"/></p>
<p>SHSE:603983 Discounted Cash Flow as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:603983 截至 2025 年 8 月的折現現金流</p>
</div><h2>MeHow Innovative (SZSE:301363)</h2>
<div class="lb-trans"><h2>MeHow Innovative (SZSE:301363)</h2>
</div><p><strong>Overview:</strong> MeHow Innovative Ltd. is a company that designs, develops, manufactures, and sells precision medical device components and products in China and internationally, with a market cap of CN¥11.33 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> MeHow Innovative Ltd. 是一家在中國及國際上設計、開發、製造和銷售精密醫療設備組件和產品的公司，市值為 CN¥113.3 億。</p>
</div><p><strong>Operations:</strong> Revenue Segments (in millions of CN¥):</p>
<div class="lb-trans"><p><strong>運營：</strong> 收入部門（以百萬 CN¥計）：</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 32.6%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 32.6%</p>
</div><p>MeHow Innovative is trading at CN¥20.03, below its estimated fair value of CN¥29.72, suggesting undervaluation based on discounted cash flow analysis. Earnings are projected to grow 22.87% annually over the next three years, although slightly lagging behind the broader Chinese market growth rate of 23.6%. Revenue growth is expected to be robust at 21.4% per year, outpacing the market average of 12.6%, despite a forecasted return on equity of only 13.1%.</p>
<div class="lb-trans"><p>MeHow Innovative 的交易價格為 CN¥20.03，低於其估計的公允價值 CN¥29.72，表明基於折現現金流分析的低估。預計未來三年收益將以每年 22.87% 的速度增長，儘管略微落後於更廣泛的中國市場增長率 23.6%。預計收入將以每年 21.4% 的速度強勁增長，超過市場平均水平 12.6%，儘管預計股本回報率僅為 13.1%。</p>
</div><ul>
<li>Upon reviewing our latest growth report, MeHow Innovative's projected financial performance appears quite optimistic.</li>
<li>Click to explore a detailed breakdown of our findings in MeHow Innovative's balance sheet health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在審查我們最新的增長報告後，MeHow Innovative 的預期財務表現似乎相當樂觀。</li>
<li>點擊探索我們在 MeHow Innovative 的資產負債表健康報告中的詳細發現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/52088d4a-b234-4222-b5fb-5f505cb6f054/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/52088d4a-b234-4222-b5fb-5f505cb6f054/chart/dcf?theme=light"/></p>
<p>SZSE:301363 Discounted Cash Flow as at Aug 2025</p>
<div class="lb-trans"><p>SZSE:301363 截至 2025 年 8 月的折現現金流</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用機會</h2>
</div><ul>
<li>Access the full spectrum of 282 Undervalued Asian Stocks Based On Cash Flows by clicking on this link.</li>
<li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li>
<li>Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接訪問基於現金流的 282 只被低估的亞洲股票的完整範圍。</li>
<li>已經擁有這些公司？將您的投資組合鏈接到 Simply Wall St，並獲取有關您股票的新警告信號的提醒。</li>
<li>利用 Simply Wall St 最大化您的投資潛力，這是一款提供全球市場洞察的綜合應用，免費提供。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>尋找新視角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健股息支付者來多樣化您的投資組合，以應對潛在的市場動盪。</li>
<li>通過分析師和管理層的樂觀前景，推動您的投資組合中顯示強勁增長潛力的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

3 只亞洲股票預計以高達 48.7% 的折扣進行交易